Sorafenib plus Hycamtin Combo Prolongs Survival in Platinum-resistant Ovarian Cancer, Phase 2 Trial Shows

Sorafenib plus Hycamtin Combo Prolongs Survival in Platinum-resistant Ovarian Cancer, Phase 2 Trial Shows
Adding sorafenib, an anti-cancer oral medicine, to Hycamtin (topotecan) chemotherapy slows the time to disease progression or death in women with platinum-resistant ovarian cancer, a Phase 2 trial shows. The trial showed that the combo therapy prolonged median progression-free survival almost seven months, compared to Hycamtin alone. The study, “Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial,” was published in the journal The Lancet Oncology. Sorafenib (produced by Bayer under the brand name 
Subscribe or to access all post and page content.